Medina Eva, Pieper Dietmar Helmut
Infection Immunology Research Group, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, 38124, Braunschweig, Germany.
Microbial Interactions and Processes Research Group, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, 38124, Braunschweig, Germany.
Curr Top Microbiol Immunol. 2016;398:3-33. doi: 10.1007/82_2016_492.
With the advent of the antibiotic era, the overuse and inappropriate consumption and application of antibiotics have driven the rapid emergence of multidrug-resistant pathogens. Antimicrobial resistance increases the morbidity, mortality, length of hospitalization and healthcare costs. Among Gram-positive bacteria, Staphylococcus aureus (MRSA) and multidrug-resistant (MDR) Mycobacterium tuberculosis, and among the Gram-negative bacteria, extended-spectrum beta-lactamase (ESBLs)-producing bacteria have become a major global healthcare problem in the 21st century. The pressure to use antibiotics guarantees that the spread and prevalence of these as well as of future emerging multidrug-resistant pathogens will be a persistent phenomenon. The unfeasibility of reversing antimicrobial resistance back towards susceptibility and the critical need to treat bacterial infection in modern medicine have burdened researchers and pharmaceutical companies to develop new antimicrobials effective against these difficult-to-treat multidrug-resistant pathogens. However, it can be anticipated that antibiotic resistance will continue to develop more rapidly than new agents to treat these infections become available and a better understanding of the molecular, evolutionary and ecological mechanisms governing the spread of antibiotic resistance is needed. The only way to curb the current crisis of antimicrobial resistance will be to develop entirely novel strategies to fight these pathogens such as combining antimicrobial drugs with other agents that counteract and obstruct the antibiotic resistant mechanisms expressed by the pathogen. Furthermore, as many antibiotics are often inappropriately prescribed, a more personalized approach based on precise diagnosis tools will ensure that proper treatments can be promptly applied leading to more targeted and effective therapies. However, in more general terms, also the overall use and release of antibiotics in the environment needs to be better controlled.
随着抗生素时代的到来,抗生素的过度使用、不当消费和应用促使多重耐药病原体迅速出现。抗菌药物耐药性增加了发病率、死亡率、住院时间和医疗成本。在革兰氏阳性菌中,金黄色葡萄球菌(耐甲氧西林金黄色葡萄球菌)和多重耐药结核分枝杆菌,以及在革兰氏阴性菌中,产超广谱β-内酰胺酶(ESBLs)的细菌已成为21世纪全球主要的医疗问题。使用抗生素的压力确保了这些以及未来新出现的多重耐药病原体的传播和流行将是一种持续存在的现象。将抗菌药物耐药性逆转回敏感性的不可行性以及现代医学中治疗细菌感染的迫切需求,使研究人员和制药公司负担沉重,需要开发对这些难以治疗的多重耐药病原体有效的新型抗菌药物。然而,可以预见的是,抗生素耐药性的发展将继续比治疗这些感染的新药物的出现更快,因此需要更好地了解控制抗生素耐药性传播的分子、进化和生态机制。遏制当前抗菌药物耐药性危机的唯一方法是制定全新的策略来对抗这些病原体,例如将抗菌药物与其他能够对抗和阻碍病原体表达的抗生素耐药机制的药物联合使用。此外,由于许多抗生素的处方往往不当,基于精确诊断工具的更个性化方法将确保能够及时应用适当的治疗方法,从而实现更有针对性和更有效的治疗。然而,更一般地说,环境中抗生素的总体使用和释放也需要得到更好的控制。